CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Targeting mutant &ITKRAS&IT with CRISPR-Cas9 controls tumor growth
Authors
Eun Ju Choi
Eun-Seo Lee
+17 more
Han Sang Kim
Hyongbum (Henry) Kim
Jae J. Song
Jae W. Choi
Jeonghong Shin
Jinu Lee
Jong In Yook
Min Goo Lee
Minjung Song
Moonkyung Kang
Sangeun Lee
Soonmyung Paik
Wonjoo Kim
Yeon-Soo Kim
Yeonsoo Joo
Yong Hoon Cha
Young-Hoon Kim
Publication date
1 October 2018
Publisher
Cold Spring Harbor Laboratory Press
Abstract
KRAS is the most frequently mutated oncogene in human tumors, and its activating mutations represent important therapeutic targets. The combination of Cas9 and guide RNA from the CRISPR-Cas system recognizes a specific DNA sequence and makes a double-strand break, which enables editing of the relevant genes. Here, we harnessed CRISPR to specifically target mutant KRAS alleles in cancer cells. We screened guide RNAs using a reporter system and validated them in cancer cells after lentiviral delivery of Cas9 and guide RNA. The survival, proliferation, and tumorigenicity of cancer cells in vitro and the growth of tumors in vivo were determined after delivery of Cas9 and guide RNA. We identified guide RNAs that efficiently target mutant OAS without significant alterations of the wild-type allele. Doxycycline-inducible expression of this guide RNA in KRAS-mutant cancer cells transduced with a lentiviral vector encoding Cas9 disrupted the mutant KRAS gene, leading to inhibition of cancer cell proliferation both in vitro and in vivo. Intra-tumoral injection of lentivirus and adeno-associated virus expressing Cas9 and sgRNA suppressed tumor growth in vivo, albeit incompletely, in immunodeficient mice. Expression of Cas9 and the guide RNA in cells containing wild-type KIZAS did not alter cell survival or proliferation either in vitro and in vivo. Our study provides a proof-of-concept that CRISPR can be utilized to target driver mutations of cancers in vitro and in vivo © 2018 Kim et al.
Similar works
Full text
Available Versions
IBS Publications Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pr.ibs.re.kr:8788114/4629
Last time updated on 06/02/2020